A week ago, Viridian Therapeutics, Inc. ( NASDAQ:VRDN ) came out with a strong set of first-quarter numbers that ...

Viridian Therapeutics recently reported positive topline results from its REVEAL‑2 phase 3 trial of elegrobart in chronic thyroid eye disease, while also completing US$125,000,014 of common stock and ...

Viridian is in the process of filing a BLA for its TED candidate elegrobart based on two positive Phase III trials.

Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease May 5, 2026 8:00 ...

By Siddhi Mahatole May 5 (Reuters) - Viridian Therapeutics said on Tuesday its experimental thyroid eye disease drug met the ...

Detailed price information for Viridian Therapeutics Inc (VRDN-Q) from The Globe and Mail including charting and trades.

According to TipRanks.com, Katkhuda is a 5-star analyst with an average return of 31.1% and a 54.0% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Mineralys ...

Viridian Therapeutics (VRDN) priced upsized concurrent public offerings totaling $350M in gross proceeds, including $225M of ...

An injectable monoclonal antibody that targets the insulin-like growth factor I receptor improved proptosis in more than half ...

US biotech Viridian Therapeutics today announced positive top-line data from the REVEAL 2 Phase III clinical trial of elegrobart in patients with chronic thyroid eye disease (TED).

Viridian Therapeutics unveiled solid results Tuesday for its experimental eye disease treatment, a potential rival to Amgen.

Phase 3 trial data showed elegrobart significantly improved proptosis and diplopia in patients with moderate to severe chronic thyroid eye disease.